Psilocybin
News You Might Have Missed: Oct 11th, 2022
The article News You Might Have Missed: Oct 11th, 2022 was originally published on Microdose.
Welcome to the News You Might Have Missed, a weekly roundup…
The article News You Might Have Missed: Oct 11th, 2022 was originally published on Microdose.
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Alberta 1st Province to Regulate Psychedelic Therapy
In big news for access to mental health treatments, Alberta has become the first Canadian province to regulate the use of psychedelics for therapy treatment.
Last Wednesday, the province announced amendments to the Mental Health Services Protection Act, including changes to rules around opioids prescriptions for people with addiction and the amendments to psychedelic use.
PharmaTher Granted U.S. Patent Covering Ketamine for Parkinson’s
Fabio Chianelli, CEO of PharmaTher: “We are pleased with the USPTO grant of the patent covering ketamine in the treatment of Parkinson’s disease and motor disorders. The US patent strengthens our intellectual property portfolio covering novel uses and delivery forms of ketamine. We are advancing the clinical development of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease, and we are seeking FDA agreement on pursuing approval under the 505(b)(2) regulatory pathway with a potential Phase 3 clinical study.”
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of DMT
“Exploring novel approaches to drug delivery can potentially simplify in-clinic administration and allow greater pharmacokinetic control of the psychedelic experience and its overall duration of hallucinogenic effects,” said Srinivas Rao, Chief Scientific Officer of atai Life Sciences. “We’re pleased to see this trial move forward as we establish the safety and tolerability of our compound.”
atai anticipates Phase 1 topline results in H1 2023.
Numinus Develops Mushroom Tea for Use in Psychedelic Research
The research behind the tea bag involved the development of processes and procedures to deliver 25mg per dose and the use of Numinus’ validated strains of Psilocybe cubensis. The tea bag will be studied in a phase 1 trial of practitioners receiving experiential training for psilocybin-assisted therapy, with the goal to be used in Numinus’ research, including trial partnerships at Cedar Clinical Research, Numinus’ clinical trial management division. The product has also been submitted to Health Canada to be included on the psilocybin supplier list for the federal Special Access Program.
Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio
MSP-2020 and MSP-2003, exhibiting a stronger and shorter acting psychedelic effect than psilocybin in preclinical testing, are selected for IND enabling studies
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
psilocybin ketamine dmt psychedelic psychedelic research therapy hallucinogenic psilocybin-assisted therapy psychedelics mindset pharma pharmather numinus mindset atai atai life sciences mushroom health canada fda research-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment